OBIO CAAP Company: ChipCare on the Business News Network's "The Disruptors"
ChipCare was featured on BNN's The Disruptors this week. The focus of the interview was ChipCare's differentiation to Theranos, our Series B raise and product pipeline, and our initial focus on low and middle income countries as a smart market entry approach.
Federal Budget Misses Opportunity to Scale and Grow Health Science Companies
The 2016 Federal Liberal budget contains funding to support a much needed Innovation Agenda and promises to build globally competitive companies. At the same time the majority of this funding is directed to incubators and accelerators, granting councils and public institutions to support basic research. In order to compete in the $9 trillion global health science economy, Canada needs to devote financial resources to health science companies at the next stage of development by investing in scale up, job creation and revenue generation.
Asthma Society of Canada: Fighting for Breath: Severe Asthma Conference
Asthma Society of Canada invites you to register for the Fighting for Breath: Severe Asthma Conference
McMaster University Partners with QoC Health on SMArTVIEW Project
March 3, 2016 QoC Health is a technology partner on McMaster University’s SMArTVIEW project. The $12.3 million project has recently received a $750,000 grant from the eHealth Innovation Partnership Program (eHIPP) from Canadian Institutes of Health Research (CIHR).
Globe & Mail Report On Business Publishes Op-Ed Penned By NACO's Co-Chairs, Ian Bandeen And Bev Tudhop
March 2, 2016 Today, the Globe and Mail Report on Business published an op-ed penned by NACO's Co-Chairs, Ian Bandeen and Bev Tudhop. Titled, "For a Fraction of the Price, Angel Investors Can Pay Huge Dividends".
CAAP Company: Komodo Openlab's Tecla Launches With Bell To Provide Customers Hands-Free Access To Mobile Technology
TORONTO, Monday, February 29, 2016 — Tecla, the assistive device that provides hands-free access to technology for those with limited upper-body mobility, is about to get a whole lot more accessible for Bell customers.
OBIO Announces CONAVI Medical WINNER of OBIO First Annual Pitches and Pitchers Competition
Last night, OBIO held its first annual PITCHES AND PITCHERS COMPETITION for OBIO Pre-CAAP and CAAP companies. We are pleased to announce that Stefano Picone, Director of Finance, CONAVI Medical, received the most votes from his peers and won the competition!!
Click here for a picture of the winner!
CAAP Company: ScarX Therapeutics closes $2 million Series A financing
Feb. 16, 2016 Toronto - ScarX Therapeutics, a Canadian biotechnology company commercializing innovative treatments for dermal scarring (fibrosis), has closed a $2 million Series A financing. The company will complete a Phase I clinical trial of its lead candidate, SCX-001, in human volunteers, with the eventual goal of creating better functional and cosmetic patient outcomes.
OBIO applauds federal funding for Natural Products Canada
February 12, 2016 – Toronto Ontario. Today, the Ontario Bioscience Innovation Organization welcomes the creation of Natural Products Canada Inc. (NPC), the nation’s newest Centre of Excellence for Commercialization and Research. Press Release. Click here for the press release.
Self Care Cataysts - Featured Article, Inc. Magazine
Grace Soyao, Founder & CEO, Self Care Catalysts Inc. writes about "Creating Breakthroughs in Entreprneurship" in 4 key steps.
Click here for the full article
Interface Biologics Announces the Extension of its Licensing Agreement with Fresenius Medical Care
TORONTO, Canada, February 9, 2016 - Interface Biologics Inc. (IBI) is pleased to announce that Fresenius Medical Care, the worlds’ largest integrated provider of dialysis products and services, has extended their exclusive licensing agreement for use of Endexo™ technology in chronic dialysis systems to cover the acute dialysis market (including CRRT).
Focal Healthcare receives 510(k) clearance from the FDA for their targeted prostate biopsy device, Fusion Bx
Toronto, ON – January 29, 2016 – Focal Healthcare Inc.TM, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for their targeted prostate biopsy device, Fusion Bx TM.
PlantForm Corporation awarded Government of Canada contract for plant-based production of anti-ricin antibody
lantForm Corporation has received a Government of Canada contract for the plant-based production of an antibody being studied by Defence Research and Development Canada (DRDC) as an antidote to ricin exposure.
Sernova Honoured as Member of the “2016 TSX Venture 50” and Ranked #4 in Life Sciences and Clean Technologies
Sernova Honoured as Member of the “2016 TSX Venture 50” and Ranked #4 in Life Sciences and Clean Technologies. Sernova resides in the top 3% of TSX Venture Exchange Companies in market performance.
TO Health! announces its evolution and Summit to make Toronto region cluster Top 5 in 10
TORONTO, Feb. 2, 2016 - TO Health! today announced its evolution and strategy to raise the profile of the Toronto Region Human Health and Sciences (HHS) cluster. The vision of the initiative is to make the Toronto region a Top 5 global health science cluster in the next 10 years.
Rna Diagnostics announces new study in chemotherapy efficacy in canine lymphoma
Rna Diagnostics Inc announced today a new study to investigate RDA as a predictor for chemotherapy efficacy in canine lymphoma in partnership with University of Guelph Institute for Comparative Cancer Investigation and the Mona Campbell Centre for Animal Cancer at the Ontario Veterinary College. This study of canine lymphoma is based on the success of an initial canine lymphoma study completed in 2014.
CAAP Company: Conavi Medical (formerly Colibri Technologies) announces FDA 510k clearance for its first product, the Foresight ICE System for Intracardiac Echocardiography
TORONTO, Jan. 14, 2016 /PRNewswire/ - Conavi Medical Inc. (formerly Colibri Technologies Inc.) has received United States (US) Food and Drug Administration (FDA) 510(k) clearance for the Foresight ICE System for intracardiac and intraluminal ultrasound visualization of cardiac and great vessel anatomy as well as visualization of other devices in the heart and great vessels of patients
NOVADAQ Announces Fourth Quarter 2015 Preliminary Unaudited Revenues and Issues 2016 Revenue Guidance
TORONTO, Jan. 11, 2016 (GLOBE NEWSWIRE) -- Novadaq Technologies Inc. (“NOVADAQ” or the “Company”) (NVDQ) (NDQ.TO), the leading developer and provider of clinically relevant fluorescence imaging solutions for use in surgical and diagnostic procedures, announced today preliminary unaudited revenue for the fourth quarter of 2015 and provided 2016 revenue guidance ahead of its participation at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
Moseda Announces Appointment of Experienced Healthcare Technology Executive
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jan. 18, 2016) - Moseda Technologies Inc. (TSX VENTURE:MSD) ("Moseda" or the "Company"), a technology company focused on developing progressive mobile health (mHealth) and telemedicine solutions for institutional and home healthcare, is pleased to announce that it has appointed industry expert Dr. Lisa Crossley, PhD., P.Eng. as CEO and Director and Mr. Sameet Kanade as President and Chairman of the Board as the Company aims to ramp up its client acquisition strategy.
OBIO Announces Pre-Capital Access Advisory Program for 2016
Toronto, Ontario, January 19, 2016 – Ontario Bioscience Innovation Organization (OBIO®) today announced the 2016 Pre-Capital Access Advisory Program (Pre-CAAP), a program in support of Ontario’s early stage bioscience companies. With access to capital as the number one challenge for bioscience start-ups in Ontario, Pre-CAAP combined with OBIO’s distinctive Capital Access Advisory Program (CAAP®) provides companies with key knowledge and insights to position them for financing and commercial success.